Skip to main content
Top
Published in: Child's Nervous System 12/2019

01-12-2019 | Glioma | Original Article

Risk stratification of pediatric high-grade glioma: a newly proposed prognostic score

Authors: Amr Muhammed, Mohamed S. Gaber, Mohamed Elbeltagy, Ahmed El Hemaly, Hala Taha, Amal Refaat, Mohamed S. Zaghluol

Published in: Child's Nervous System | Issue 12/2019

Login to get access

Abstract

Objectives

High-grade glioma (HGG) is a clinical challenge. Radiation Therapy Oncology Group Recursive Partitioning Analysis (RTOG-RPA) for HGG remains the standard for assessing the prognosis of adult HGG. This study assesses the validity of the RTOG-RPA to be applied to pediatric HGG.

Methods

A retrospective study was conducted on 59 pediatric HGG treated in the Children’s Cancer Hospital, Egypt (CCHE) between 2007 and 2016. Several factors were studied as predictors for the disease survival, including age, gender, increased intracranial hypertension, tumor characteristics and pathology, CSF seeding, performance status, post-surgical residual, and radiation dose. The statistically significant results were integrated into a Cox-regression model to develop a prognostic risk score.

Results

Kaplan-Meier statistics identified 13 factors that impacted the overall survival. However, Cox model showed that the histological grade IV [HR 14.2, 95%CI; (3.5–57), P < 0.0001], thalamic infiltration [HR 8.7; 95%CI; (2.9–25.9), P < 0.0001], PS ≥ 60 [HR 0.317; 95%CI; (0.13–0.776); P = 0.012], and maximum tumor dimension > 3.3 cm [HR 10.2; 95%CI; (1.58–65.89); P = 0.015] were the independent variables that predicted the overall survival. A risk score was proposed based on the presence of one or more of these factors. The median OS for the low risk (score 0–1), the intermediate-low risk (score 2), the intermediate-high risk (score 3), and the high risk (score 4) were 40, 18.5, 9.5, and 2.5 months, respectively, (P < 0.0001).

Conclusion

The proposed model and risk score could stratify pediatric patients as the RTOG-RPA do for the adults.
Literature
2.
go back to reference Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710CrossRef Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710CrossRef
3.
go back to reference Duffner PK, Krischer JP, Burger PC, Cohen ME, Backstrom JW, Horowitz ME, Sanford RA, Friedman HS, Kun LE (1996) Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J Neuro-Oncol 28:245–256CrossRef Duffner PK, Krischer JP, Burger PC, Cohen ME, Backstrom JW, Horowitz ME, Sanford RA, Friedman HS, Kun LE (1996) Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J Neuro-Oncol 28:245–256CrossRef
6.
go back to reference Kaatsch P, Rickert CH, Kuhl J, Schuz J, Michaelis J (2001) Population-based epidemiologic data on brain tumors in German children. Cancer 92:3155–3164CrossRef Kaatsch P, Rickert CH, Kuhl J, Schuz J, Michaelis J (2001) Population-based epidemiologic data on brain tumors in German children. Cancer 92:3155–3164CrossRef
10.
go back to reference Mackay A, Burford A, Molinari V, Jones DTW, Izquierdo E, Brouwer-Visser J, Giangaspero F, Haberler C, Pietsch T, Jacques TS, Figarella-Branger D, Rodriguez D, Morgan PS, Raman P, Waanders AJ, Resnick AC, Massimino M, Garre ML, Smith H, Capper D, Pfister SM, Wurdinger T, Tam R, Garcia J, Thakur MD, Vassal G, Grill J, Jaspan T, Varlet P, Jones C (2018) Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial. Cancer Cell 33:829–842 e825. https://doi.org/10.1016/j.ccell.2018.04.004 CrossRefPubMedPubMedCentral Mackay A, Burford A, Molinari V, Jones DTW, Izquierdo E, Brouwer-Visser J, Giangaspero F, Haberler C, Pietsch T, Jacques TS, Figarella-Branger D, Rodriguez D, Morgan PS, Raman P, Waanders AJ, Resnick AC, Massimino M, Garre ML, Smith H, Capper D, Pfister SM, Wurdinger T, Tam R, Garcia J, Thakur MD, Vassal G, Grill J, Jaspan T, Varlet P, Jones C (2018) Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial. Cancer Cell 33:829–842 e825. https://​doi.​org/​10.​1016/​j.​ccell.​2018.​04.​004 CrossRefPubMedPubMedCentral
11.
go back to reference Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569. https://doi.org/10.1200/JCO.2005.04.5963 CrossRefPubMed Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569. https://​doi.​org/​10.​1200/​JCO.​2005.​04.​5963 CrossRefPubMed
12.
go back to reference Paravati AJ, Heron DE, Landsittel D, Flickinger JC, Mintz A, Chen YF, Huq MS (2011) Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neuro-Oncol 104:339–349. https://doi.org/10.1007/s11060-010-0499-8 CrossRef Paravati AJ, Heron DE, Landsittel D, Flickinger JC, Mintz A, Chen YF, Huq MS (2011) Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neuro-Oncol 104:339–349. https://​doi.​org/​10.​1007/​s11060-010-0499-8 CrossRef
13.
go back to reference Salcman M, Scholtz H, Kaplan RS, Kulik S (1994) Long-term survival in patients with malignant astrocytoma. Neurosurgery 34:213-219; discussion 219-220 Salcman M, Scholtz H, Kaplan RS, Kulik S (1994) Long-term survival in patients with malignant astrocytoma. Neurosurgery 34:213-219; discussion 219-220
14.
go back to reference Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran WJ Jr (1998) Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51–55CrossRef Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran WJ Jr (1998) Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51–55CrossRef
Metadata
Title
Risk stratification of pediatric high-grade glioma: a newly proposed prognostic score
Authors
Amr Muhammed
Mohamed S. Gaber
Mohamed Elbeltagy
Ahmed El Hemaly
Hala Taha
Amal Refaat
Mohamed S. Zaghluol
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Child's Nervous System / Issue 12/2019
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-019-04257-2

Other articles of this Issue 12/2019

Child's Nervous System 12/2019 Go to the issue